A new era for the management of metastatic melanoma Journal Article
| Authors: | Koneru, M.; Carvajal, R. D. |
| Article Title: | A new era for the management of metastatic melanoma |
| Abstract: | Our increasing understanding of the underlying biology of melanoma and tumor immunology has led to the development of a number of drugs that are showing great promise for the treatment of this disease. In 2011, the US FDA approved two new agents for the management of metastatic melanoma. Both ipilimumab, a fully human IgG1 antibody against cytotoxic T-lymphocyte antigen 4, and vemurafenib, a small molecule inhibitor of mutated BRAF, were approved based upon the ability of each of these agents to improve survival in patients with advanced disease, something not achieved with any other therapy tested thus far. Herein, we review the clinical development of these agents and discuss other promising immunological and molecular therapies being investigated for use in melanoma. © 2012 Expert Reviews Ltd. |
| Keywords: | signal transduction; mitogen activated protein kinase; cancer survival; unclassified drug; gene mutation; constipation; fatigue; review; squamous cell carcinoma; hepatitis; sorafenib; placebo; sunitinib; advanced cancer; cancer combination chemotherapy; diarrhea; dose response; drug dose reduction; drug efficacy; recommended drug dose; treatment duration; treatment planning; drug approval; skin manifestation; temozolomide; drug megadose; antineoplastic agent; imatinib; stem cell factor receptor; alpha2b interferon; dacarbazine; glycoprotein gp 100; interleukin 2; ipilimumab; cancer immunotherapy; melanoma; metastasis; multiple cycle treatment; skin defect; mitogen activated protein kinase inhibitor; nausea; skin cancer; dasatinib; monoclonal antibody; abdominal pain; arthralgia; coughing; pruritus; rash; gene expression regulation; chemotherapy induced emesis; immunotherapy; colitis; targeted therapy; brain cancer; clinical effectiveness; kit; corticosteroid; nilotinib; autoimmune disease; alopecia; b raf kinase; braf; endocrine disease; immunopathology; keratoacanthoma; metastatic melanoma; adrenal insufficiency; molecular pathology; b raf kinase inhibitor; molecularly targeted therapy; decreased appetite; blister; hypophysitis; hypopituitarism; vitiligo; thyroiditis; mdx 1106; selumetinib; photosensitivity disorder; vemurafenib; gnaq/11; dabrafenib; trametinib; maintenance chemotherapy |
| Journal Title: | Expert Review of Dermatology |
| Volume: | 7 |
| Issue: | 1 |
| ISSN: | 1746-9872 |
| Publisher: | Informa Healthcare |
| Date Published: | 2012-01-01 |
| Start Page: | 27 |
| End Page: | 35 |
| Language: | English |
| DOI: | 10.1586/edm.11.83 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 March 2012" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work